Myalgic encephalomyelitis/chronic fatigue syndrome

Myalgic encephalomyelitis/chronic fatigue syndrome
Other namesPost-viral fatigue syndrome (PVFS), systemic exertion intolerance disease (SEID)[1]: 20 
Icons of the four key ME/CFS symptoms: low battery for profound fatigue, weak muscle for post-exertional malaise, bed for sleep problems and crossed wires in brain for cognitive difficulties.
The four primary symptoms of ME/CFS according to the National Institute for Health and Care Excellence
SpecialtyRheumatology, rehabilitation medicine, endocrinology, infectious disease, neurology, immunology, general practice, paediatrics, other specialists in ME/CFS[2]: 58 
SymptomsWorsening of symptoms with activity, long-term fatigue, sleep problems, others[3]
Usual onsetPeaks at 10–19 and 30–39 years old[4]
DurationLong-term[5]
CausesUnknown[6]
Risk factorsBeing female, family history, viral infections[6]
Diagnostic methodBased on symptoms[7]
TreatmentSymptomatic[8]
PrevalenceAbout 0.17% to 0.89% (pre-COVID-19 pandemic)[9]

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a disabling chronic illness. People with ME/CFS experience profound fatigue that does not go away with rest, as well as sleep issues and problems with memory or concentration. The hallmark symptom is post-exertional malaise, a worsening of the illness which can start immediately or hours to days after even minor physical or mental activity. This "crash" can last from hours or days to several months. Further common symptoms include dizziness or faintness when upright and pain.[3][10]

The cause of the disease is unknown.[11] ME/CFS often starts after an infection, such as mononucleosis.[12] It can run in families, but no genes that contribute to ME/CFS have been confirmed.[13] ME/CFS is associated with changes in the nervous and immune systems, as well as in energy production.[14] Diagnosis is based on symptoms and a differential diagnosis because no diagnostic test such as a blood test or imaging is available.[7][15][16][17]

Symptoms of ME/CFS can sometimes be treated and the illness can improve or worsen over time, but a full recovery is uncommon.[12][18] No therapies or medications are approved to treat the condition, and management is aimed at relieving symptoms.[2]: 29  Pacing of activities can help avoid worsening symptoms, and counselling may help in coping with the illness.[8] Before the COVID-19 pandemic, ME/CFS affected two to nine out of every 1,000 people, depending on the definition.[9] However, many people fit ME/CFS diagnostic criteria after contracting long COVID.[19] ME/CFS occurs more often in women than in men. It is more common in middle age, but can occur at all ages, including childhood.[20]

ME/CFS has a large social and economic impact, and the disease can be socially isolating.[21] About a quarter of those affected are unable to leave their bed or home.[10]: 3  People with ME/CFS often face stigma in healthcare settings, and care is complicated by controversies around the cause and treatments of the illness.[22] Doctors may be unfamiliar with ME/CFS, as it is often not fully covered in medical school.[19] Historically, research funding for ME/CFS has been far below that of diseases with comparable impact.[23]

  1. ^ Cite error: The named reference IOM2015 was invoked but never defined (see the help page).
  2. ^ a b "Myalgic Encephalomyelitis (Or Encephalopathy)/Chronic Fatigue Syndrome: Diagnosis and Management: NICE Guideline". National Institute for Health and Care Excellence (NICE). 29 October 2021. Archived from the original on 8 February 2024. Retrieved 9 March 2024.
  3. ^ a b "Symptoms of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". U.S. Centers for Disease Control and Prevention (CDC). 10 May 2024. Archived from the original on 17 May 2024. Retrieved 17 May 2024.
  4. ^ Cite error: The named reference pmid31379194 was invoked but never defined (see the help page).
  5. ^ "Myalgic Encephalomyelitis (Or Encephalopathy)/Chronic Fatigue Syndrome: Diagnosis and Management: Information for the Public". National Institute for Health and Care Excellence (NICE). 29 October 2021. Archived from the original on 4 April 2024. Retrieved 24 March 2024.
  6. ^ a b Cite error: The named reference pmid37793728 was invoked but never defined (see the help page).
  7. ^ a b Cite error: The named reference pmid37226227 was invoked but never defined (see the help page).
  8. ^ a b "Manage Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". U.S. Centers for Disease Control and Prevention (CDC). 10 May 2024. Archived from the original on 18 May 2024. Retrieved 18 May 2024.
  9. ^ a b Lim EJ, Ahn YC, Jang ES, Lee SW, Lee SH, Son CG (February 2020). "Systematic Review and Meta-Analysis Of the Prevalence of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)". Journal of Translational Medicine. 18 (1): 100. doi:10.1186/s12967-020-02269-0. PMC 7038594. PMID 32093722.
  10. ^ a b Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (17 April 2023). Myalgische Enzephalomyelitis / Chronic Fatigue Syndrome (ME/CFS): Aktueller Kenntnisstand [Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): current state of knowledge] (PDF) (in German). Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. ISSN 1864-2500. Archived (PDF) from the original on 2 November 2023. Retrieved 8 November 2023.
  11. ^ Cite error: The named reference CDC_Clinical2024 was invoked but never defined (see the help page).
  12. ^ a b Bateman L, Bested AC, Bonilla HF, Chheda BV, Chu L, Curtin JM, et al. (November 2021). "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of Diagnosis and Management". Mayo Clinic Proceedings. 96 (11): 2861–2878. doi:10.1016/j.mayocp.2021.07.004. PMID 34454716. S2CID 237419583.
  13. ^ Dibble JJ, McGrath SJ, Ponting CP (September 2020). "Genetic Risk Factors of ME/CFS: A Critical Review". Human Molecular Genetics. 29 (R1): R117 – R124. doi:10.1093/hmg/ddaa169. PMC 7530519. PMID 32744306.
  14. ^ Annesley SJ, Missailidis D, Heng B, Josev EK, Armstrong CW (March 2024). "Unravelling Shared Mechanisms: Insights from Recent ME/CFS Research to Illuminate Long COVID Pathologies". Trends in Molecular Medicine. 30 (5): 443–458. doi:10.1016/j.molmed.2024.02.003. PMID 38443223.
  15. ^ "Myalgic encephalomyelitis (Chronic fatigue syndrome) - Symptoms, diagnosis and treatment | BMJ Best Practice US". bestpractice.bmj.com. Retrieved 21 October 2024.
  16. ^ "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (CFS) | Diseases & Conditions | 5MinuteConsult". 5minuteconsult.com. Retrieved 25 November 2024.
  17. ^ Cite error: The named reference pmid28033311 was invoked but never defined (see the help page).
  18. ^ CDC (22 May 2024). "Manage Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Retrieved 8 April 2025.
  19. ^ a b Davis HE, McCorkell L, Vogel JM, Topol EJ (March 2023). "Long COVID: Major Findings, Mechanisms and Recommendations". Nature Reviews. Microbiology. 21 (3): 133–146. doi:10.1038/s41579-022-00846-2. PMC 9839201. PMID 36639608.
  20. ^ Cite error: The named reference CDC_Basics was invoked but never defined (see the help page).
  21. ^ Boulazreg, S, Rokach A (17 July 2020). "The Lonely, Isolating, and Alienating Implications of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Healthcare. 8 (4): 413–433. doi:10.3390/healthcare8040413. ISSN 2164-1846. PMC 7711762. PMID 33092097.
  22. ^ Hussein S, Eiriksson L, MacQuarrie M, Merriam S, Dalton M, Stein E, et al. (2024). "Healthcare System Barriers Impacting the Care of Canadians with Myalgic Encephalomyelitis: A Scoping Review". Journal of Evaluation in Clinical Practice. 30 (7): 1337–1360. doi:10.1111/jep.14047. ISSN 1356-1294. PMID 39031904.
  23. ^ Tyson S, Stanley K, Gronlund TA, Leary S, Emmans Dean M, Dransfield C, et al. (2022). "Research Priorities for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): The Results of a James Lind Alliance Priority Setting Exercise". Fatigue: Biomedicine, Health & Behavior. 10 (4): 200–211. doi:10.1080/21641846.2022.2124775. ISSN 2164-1846. S2CID 252652429.

© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search